DOI: 10.7759/cureus.46717

# **Pericarditis of Polyarteritis Nodosa**

Robert Ambrogetti <sup>1</sup>, Omer Taha <sup>1</sup>, Baseer Awan <sup>2</sup>, Ahsan Memon <sup>2</sup>, Kehinde O. Sunmboye <sup>3, 2</sup>

Review began 09/25/2023 Review ended 10/04/2023 Published 10/09/2023

© Copyright 2023

Ambrogetti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Medicine, University Hospitals of Leicester NHS Trust, Leicester, GBR 2. Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, GBR 3. Health Sciences, University of Leicester, Leicester, GBR

Corresponding author: Robert Ambrogetti, robertambrogetti@doctors.org.uk

# **Abstract**

Polyarteritis nodosa (PAN) is a rare systemic vasculitis characterised by necrotising inflammation of medium-sized arteries. PAN can affect patients of any age, gender, or ethnic background. Its highest incidence is in the fifth-sixth decade of life, with a slight male-to-female predilection. PAN can be idiopathic or secondary to a multitude of systemic conditions, such as infection, haematological malignancy, or autoinflammatory disorders. PAN has a broad spectrum of possible clinical manifestations the most common being constitutional symptoms, such as fever and myalgia. While cardiac involvement is well-described and is a common cause of mortality, it is exceedingly uncommon as the initial presentation. Below, we describe a case of a female in her 60s who presented with pericarditis as the first manifestation of PAN.

Categories: Cardiology, Internal Medicine, Rheumatology Keywords: rheumatology, cardiology, chest pain syndrome, polyarteritis, pericarditis

### Introduction


Polyarteritis nodosa (PAN) is a rare systemic vasculitis characterised by necrotising inflammation of medium-sized arteries. Small branching arteries can sometimes be involved. However, arterioles, venules, and capillaries are spared. PAN can affect patients of any age, gender, or ethnic background. Its highest incidence is in the fifth-sixth decade of life with a slight male-to-female (1.5:1) predilection. PAN has a prevalence of around 33 per million and an incidence of 0-1.6 cases per million per year [1,2].

PAN can be idiopathic or secondary to a multitude of systemic conditions, such as infection, haematological malignancy, or autoinflammatory disorders. The spectrum of disease in PAN ranges from single-organ involvement to multi-organ failure. As a result, PAN has a broad spectrum of possible clinical manifestations. Constitutional symptoms, such as fever and myalgia, are the most common. However, neurological, renal, dermatological, gastrointestinal, cardiovascular, and pulmonary manifestations are also reported. While cardiac involvement is well-described and is a common cause of mortality, it is exceedingly uncommon as the initial presentation. Below, we describe a case of a female in her 60s who presented with pericarditis as the first manifestation of PAN.

### **Case Presentation**

A woman in her 60s was transferred to the coronary care unit (CCU) from the local accident and emergency department with a three-day history of pleuritic central chest pain, which was positional in nature with associated intermittent palpitations. She denies previous similar episodes and reports no syncope, presyncope, recent illness, or shortness of breath. The patient has a past medical history of Raynaud's phenomenon, gastroesophageal reflux, and mild sleep apnoea for which she uses nocturnal continuous positive airway pressure. At the time, the patient was not taking any regular medications and reported no known allergies. The patient is a retired, independent, non-smoker with minimal alcohol consumption. The patient's mother passed away from aortic dissection, and one of the patient's children has a diagnosis of ulcerative colitis.


Her ECG on presentation in Figure 1 showed an irregularly irregular rhythm with a lack of P waves, widespread ST-segment elevation with concave morphology, no reciprocal changes, subtle PR elevation in lead aVR, and PR depression in leads aVF and 2. These ECG features in the clinical context are highly suggestive of pericarditis with concurrent atrial fibrillation.



# FIGURE 1: ECG - Pericarditis and atrial fibrillation

ECG showing widespread ST elevations with concave morphology and irregular rhythm with no P waves consistent with Atrial Fibrillation and pericarditis.

During the evening of admission, the patient complained of chest pain radiating to the back during an episode of hypotension (BP 80/45). Hence, a CT aorta was performed, which excluded aortic dissection. Instead, the CT aorta showed aneurysms throughout the mesenteric vascular system (Figure 2). Aneurysmal coronary arteries, diffusely aneurysmal right hepatic artery, axillary aneurysms, bi-apical pulmonary fibrosis, and shallow pericardial effusion were also noted.



### FIGURE 2: CT - Mesenteric aneurysms

10 mm fusiform aneurysm of the jejunal branch of the superior mesenteric artery, and 9 mm distal superior mesenteric artery aneurysm with further small areas of focal vascular ectasia of the ileal branches (arrows)

The patient was treated for pericarditis with colchicine and ibuprofen, anticoagulated for atrial fibrillation with rivaroxaban (initiated one-week post-discharge), and rate-controlled with bisoprolol. Based on the CT findings and presentation, an underlying aetiology of vasculitis was suspected. As a result, the patient was reviewed by the rheumatology service, who advised on vasculitis and infectious screenings. The results of which are seen in Table 1.

Initial Admission Blood tests						
Routine	1st Admission	1st DC	OP F/U	2nd Admission	2nd DC	Ref Range
WBC	10.70	6.90	7.70	10	10.4	4.0-11.0
Haemoglobin	110.00	124.00	120.00	117	106	115-150
CRP	166.00	118.00	20.00	104	101	0-10
eGFR	>90	>90	>90	>90	>90	
Urea	3.5	2.8	4.4	3.5	4.4	2.5-7.8
Sodium	129.00	135.00	133.00	136	136	133-146
Potassium	4.50	4.60	4.30	4.6	4	3.5-5.3
Other						
TSH	1.10					
Troponin (2nd)	23 (27)					
D dimer	0.70					0.00-0.50
INR	1.20					
Creatinine Kinase	42.00					25-200
Vasculitis screen						
ANA	Negative					
ENA (Ro, La, Sm, U1RNP, RNP70, CENP, Jo-1, ScI-70)	Negative					
Rheumatoid factor	9.00					0-12.5
MPO-ANCA	<1.0					0-6
PR3-ANCA	<0.6					0-5
C3	1.30					0.75-1.65
C4	0.27					0.14-0.54
Infectious screen						
HIV 1 & 2 combined ab/ag test	Not detected by	EIA				
Hepatitis B	Not detected by	EIA				
Hepatitis C	Not detected by	EIA				
QuantiFERON TB Gold Plus	Negative					
QuantiFERON Antigen 1	0.00 IU/mL					
QuantiFERON Antigen 2	0.00 IU/mL					
QuantiFERON Mitogen	1.00 IU/mL					
Glandular fever screen	Negative					

# **TABLE 1: Blood tests**

Key: DC = discharge; OP = outpatient; F/U = Follow-up

Good clinical and biochemical improvement was seen in response to this treatment (Table  $\it{I}$ ). The patient was discharged and followed up in the rheumatology clinic several days after discharge.

Following this, 15 days after the initial discharge, the patient represented to the hospital with pre-syncope and shortness of breath. Her ECG at the time showed electrical alternans consistent with significant

pericardial effusion.

Her echocardiogram confirmed a large pericardial effusion with features of incipient cardiac tamponade, as seen in Figure 3. Her pericardial effusion progressed, and right ventricular collapse developed, causing haemodynamic compromise. As a result, a pericardial drain was placed, and 450 ml of slight pink straw-coloured pericardial fluid was drained. The drain was removed two days later with a resolution of the pericardial effusion.




FIGURE 3: Echocardiogram with large pericardial effusion

Echocardiogram image showing global pericardial effusion around the left and right ventricles in the parasternal long-axis view. Effusion measuring 1.8 cm around the left ventricle (arrows).

After removing the pericardial drain, the patient had an uneventful stay free of complications. A diagnosis of polyarteritis nodosa was made on the basis of the clinical features and angiographic findings. As a result, the patient was started on prophylactic Co-trimoxazole, a reducing prednisolone dose and bone protection medication. The patient was discharged with the plan to start cyclophosphamide as an outpatient with rheumatology follow-up. The patient has since reported intermittent episodes of asymptomatic low blood pressure, palpitations, and chest discomfort. Hence, she has remained under cardiology and rheumatology follow-up as an outpatient.

### **Discussion**

Acute pericarditis is a relatively common presentation that accounts for 5% of non-ischaemic chest pain in emergency departments [3,4]. It is generally considered self-limiting and not life-threatening when myocardial infarction, dissection, and cardiac tamponade have been excluded [4]. Most cases are considered viral in origin, and the exact aetiology is not identified in most cases [4]. Such cases are labelled as idiopathic pericarditis. Most idiopathic pericarditis responds to conventional treatment with non-steroidal anti-inflammatory medication and colchicine, with little to no reoccurrence [5]. This case highlights the importance of recognising the autoimmune causes of pericarditis, such as PAN. Such cases of pericarditis may not have sustained response to conventional treatment, which may predispose them to relapse and more severe complications such as cardiac tamponade, as seen in this case. Furthermore, if left untreated, there is approximately only a 13% five-year survival rate in PAN [6,7]. With prompt recognition and treatment with modern immunotherapy (e.g., steroids and cyclophosphamide), PAN's five- and 10-year survival rates improve to around 83% and 74%, respectively [8].

The variety of clinical presentations and symptoms that can be seen in PAN is shown in Table 2. Cardiac manifestations of PAN have been documented since the first case report from Kussmaul and Maier (1866), who described nodular coronary inflammation [9]. In histological studies at autopsy in 1962, pericardial involvement was reported to be as high as 19% [10]. However, over 90% of these cases were pericarditis secondary to uraemia related to renal failure [10]. A histological retrospective review of 66 cases of PAN from 1926 to 1958 found 22 cases of PAN to have evidence of pericarditis [11]. Of these 22, nine (13%) cases were considered to have non-uremic pericarditis or pericarditis directly caused by polyarteritis nodosa, also known as pericarditis of PAN [11]. The Chapel Hill Consensus Conference (CHCC) formally distinguished microscopic polyangiitis and PAN in 1994 [12]. Hence, reports on the incidence, prevalence, and

manifestations of PAN in the above studies, which predate 1994, must be interpreted cautiously, as many cases of microscopic polyangiitis were likely included. Modern studies suggest that pericarditis, as a clinical manifestation of PAN, is reported in around 5% of cases [8]. Although this study did not mention pericarditis related to uraemia, 66% of the cohort had renal involvement. Hence, the number of patients with pericarditis secondary to uraemia or primary pericarditis of PAN is unknown. Generally, pericarditis of PAN, such as in our case, is uncommon. To the author's knowledge, pericarditis as the first presentation of PAN has yet to be reported.

Clinical Manifestations of Polyarteritis Nodosa	
Manifestation	Frequency (%)
Constitutional (Weight loss, myalgia, fever)	93
Neurological (Neuropathy, Stroke, Delirium)	79
Urological (Orchitis, haematuria)	50
Dermatological (nodules, purpura, livedo)	50
Renal injury	51
Joint pain	49
Gastrointestinal (abdominal pain, bleeding, perforation, cholecystitis, appendicitis, pancreatitis)	38
Hypertension	34
Cardiovascular (cardiomyopathy, pericarditis, digital ischaemia)	22
Pulmonary	12
Ophthalmologic	9

### **TABLE 2: Clinical manifestations**

Adapted from Ref. (8)

There is no consensus on the pathogenetic mechanism of PAN. It is thought that the wide variation in clinical manifestations seen in Table 2 likely represents multiple separate pathogenic mechanisms from a spectrum of underlying diseases, resulting in the same constellation of clinical phenotypic features [13]. Over time many underlying disease states have been associated with PAN, further supporting this theory. Table 3 summarises the possible disease associations. The most well-known form of secondary PAN is caused by hepatitis B infection [14]. Hepatitis C and hairy cell leukaemia have also been reported to play a role in the pathogenesis of some cases [15,16]. PAN-like vasculitis has also been reported in monogenic auto-inflammatory conditions such as familial Mediterranean fever, adenosine deaminase-2 deficiency, and VEXAS syndrome [14,17].

nfection		
	Hepatitis B	
	Hepatitis C	
	Parvovirus B19	
	HIV	
	EBV	
Haematological disorder	'S	
	Hairy cell leukemia	
	Myelodysplastic syndromes	
Monogenic causes		
	Familial Mediterranean fever	
	Adenosine deaminase-2 deficiency	

#### **TABLE 3: Conditions associated with PAN**

Adapted from Ref. (14)

The incidence of PAN has decreased with the identification of secondary causes and the delineation of idiopathic PAN. Contemporary evidence suggests the incidence of PAN is 0-1.6 cases per million per year, and the prevalence is up to 33 cases per million in European populations [1]. Although PAN can affect patients of any gender, age, or ethnicity, its peak incidence is in the fifth and sixth decades of life, as seen in our patient [1,2].

With no common consensus or validated diagnostic criteria, the diagnosis of PAN is largely based on symptom recognition, clinical suspicion, imaging, biopsy, and the exclusion of secondary causes [14]. The American College of Rheumatology criteria for the classification of PAN, seen in Table 4, can aid the diagnosis and clinical decision for further investigation [18].

#### American College of Rheumatology PAN Classification Criteria

Weight loss > 4 kg

Livedo reticularis

Testicular pain or sensitivity

Diffuse myalgia, muscle weakness, or leg tenderness

Mono or polyneuropathy

Diastolic pressure > 90mm Hg

Renal failure (BUN > 14.3 mmol / L or serum creatinine > 132 umol/L)

Presence of HBV antigen or HBV antibodies in serum

Angiographic abnormalities (aneurysm and/or occlusion of visceral arteries)

Biopsy of a small or medium-sized artery showing neutrophils in the arterial wall

#### **TABLE 4: ACR PAN classification criteria**

Adapted from Ref. (18)

PAN, polyarteritis nodosa

ACR, American College of Rheumatology

Ideally, the diagnosis should be confirmed histologically with a biopsy of an affected organ [14]. However, muscle and nerve biopsies diagnose 75% of cases, renal biopsies are not advised, and cutaneous biopsies show vasculitis in roughly 50% of patients [14]. When a biopsy is not possible such as in our case, the diagnosis can be made through angiography [14,19]. Angiographic evidence of mesenteric, hepatic, and renal focal segmental aneurysms is seen in up to 90% of cases of PAN [14]. Current guidelines recommend CT or MR angiography as noninvasive diagnostic techniques for diagnosis, baseline assessment of disease activity, and determining disease severity [19].

### **Conclusions**

Pericarditis is often considered a relatively benign condition where no specific cause is often found. However, this case shows that not all cases of pericarditis are self-limiting, underscoring the importance of identifying an aetiology and ruling out systemic diseases, such as vasculitis. Pericarditis caused by vasculitis, specifically PAN, can be refractory to conventional pericarditis treatment and potentially life-threatening. Modern treatment significantly reduces the mortality associated with PAN, highlighting the importance of identifying the aetiology. Despite once a problematic diagnosis to confirm, current guidelines suggest that CT angiography can help confirm the diagnosis, as illustrated in this case. Vasculitis such as PAN should be considered in cases of pericarditis with evidence of multisystem involvement.

### **Additional Information**

### **Author Contributions**

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Robert Ambrogetti, Omer Taha, Ahsan Memon, Kehinde O. Sunmboye, Baseer Awan

**Acquisition, analysis, or interpretation of data:** Robert Ambrogetti, Omer Taha, Kehinde O. Sunmboye, Baseer Awan

Drafting of the manuscript: Robert Ambrogetti, Omer Taha, Ahsan Memon, Baseer Awan

**Critical review of the manuscript for important intellectual content:** Robert Ambrogetti, Omer Taha, Ahsan Memon, Kehinde O. Sunmboye, Baseer Awan

Supervision: Ahsan Memon, Kehinde O. Sunmboye

#### **Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

- Mahr A, Guillevin L, Poissonnet M, Aymé S: Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004, 51:92-9. 10.1002/art.20077
- Watts RA, Lane SE, Bentham G, Scott DGI: Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000, 43:414-9. 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0
- Kytö V, Sipilä J, Rautava P: Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014, 130:1601-6. 10.1161/CIRCULATIONAHA.114.010376
- Chiabrando JG, Bonaventura A, Vecchié A, et al.: Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:76-92. 10.1016/j.jacc.2019.11.021
- Adler Y, Charron P, Imazio M, et al.: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart I. 2015. 36:2921-64. 10.1093/eurhearti/ehy318
- 6. Balow JE: Renal vasculitis. Kidney Int. 1985, 27:954-64. 10.1038/ki.1985.104
- Frohnert PP, Sheps SG: Long-term follow-up study of periarteritis nodosa. Am J Med. 1967, 43:8-14. 10.1016/0002-9343(67)90144-1
- 8. Pagnoux C, Seror R, Henegar C, et al.: Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010, 62:616-26. 10.1002/art.27240
- Matteson EL: A history of early investigation in polyarteritis nodosa. Arthritis Care Res (Hoboken). 1999, 12:294-302. 10.1002/1529-0131(199908)12:4<294::AID-ART8>3.0.CO;2-6
- Schrader ML, Hochman JS, Healy Bulkley B: The heart in polyarteritis nodosa: a clinicopathologic study. Am Heart J. 1985, 109:1353-9. 10.1016/0002-8703(85)90365-5
- Holsinger DR, Osmundson PJ, Edwards JE: The heart in periarteritis nodosa. Circulation. 1962, 25:610-8.
  10.1161/01.cir.25.4.610
- 12. Selga D, Mohammad A, Sturfelt G, Segelmark M: Polyarteritis nodosa when applying the Chapel Hill nomenclature—a descriptive study on ten patients. Rheumatology (Oxford). 2006, 45:1276-81. 10.1093/rheumatology/kel091
- Ozen S: The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol. 2017, 13:381-6. 10.1038/nrrheum.2017.68
- 14. Puéchal X: Polyarteritis nodosa: state of the art. Jt Bone Spine. 2022, 89:105320.
- Ramos-Casals M, Muñoz S, Medina F, et al.: Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol. 2009, 36:1442-8. 10.3899/irheum.080874
- Hasler P, Kistler H, Gerber H: Vasculitides in hairy cell leukemia. Semin Arthritis Rheum. 1995, 25:134-42.
  10.1016/S0049-0172(95)80026-3
- Beck DB, Ferrada MA, Sikora KA, et al.: Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020, 383:2628-38. 10.1056/NEJMoa2026834
- Lightfoot RW Jr, Michel BA, Bloch DA, et al.: The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990, 33:1088-93. 10.1002/art.1780330805
- Chung SA, Gorelik M, Langford CA, et al.: 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol. 2021, 73:1384-93. 10.1002/art.41776